Multiple Novel Inhibitors of the NorA Multidrug Transporter of Staphylococcus aureus

AUTOR(ES)

Markham, Penelope N.

FONTE

American Society for Microbiology

RESUMO

The multidrug transporter NorA contributes to the resistance of Staphylococcus aureus to fluoroquinolone antibiotics by promoting their active extrusion from the cell. Previous studies with the alkaloid reserpine, the first identified inhibitor of NorA, indicate that the combination of a chemical NorA inhibitor with a fluoroquinolone could improve the efficacy of this class of antibiotics. Since reserpine is toxic to humans at the concentrations required to inhibit NorA, we sought to identify new inhibitors of NorA that may be used in a clinical setting. Screening of a chemical library yielded a number of structurally diverse inhibitors of NorA that were more potent than reserpine. The new inhibitors act in a synergistic manner with the most widely used fluoroquinolone, ciprofloxacin, by substantially increasing its activity against both NorA-overexpressing and wild-type S. aureus isolates. Furthermore, the inhibitors dramatically suppress the emergence of ciprofloxacin-resistant S. aureus upon in vitro selection with this drug. Some of these new inhibitors, or their derivatives, may prove useful for augmentation of the antibacterial activities of fluoroquinolones in the clinical setting.

Documentos Relacionados

• Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter.
• Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus.
• Evidence for the Existence of a Multidrug Efflux Transporter Distinct from NorA in Staphylococcus aureus
• Expression of the Multidrug Resistance Transporter NorA from Staphylococcus aureus Is Modified by a Two-Component Regulatory System
• A Mutation in the 5′ Untranslated Region Increases Stability of norA mRNA, Encoding a Multidrug Resistance Transporter of Staphylococcus aureus